Tenosynovial giant cell tumor (TGCT) is a rare, nonmalignant tumor affecting the synovial lining of joints, bursae, and tendon sheaths. It is a potentially locally aggressive disease with high recurrence rates. In addition to agents used off-label for TGCT, the FDA recently approved the first medication specifically indicated for adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. This educational activity will ensure clinicians are better informed of the benefits and risks of TGCT treatment approaches, more prepared to help patients understand the implications of treatment decisions, and better able to support a joint decision-making process that takes into account patient objectives, treatment efficacy and safety, and the impact of treatment choice on the patient’s quality of life. This activity is jointly sponsored by The Postgraduate Institute for Medicine (PIM) and Spire Learning. It is supported by an independent educational grant from Daiichi Sankyo, Inc.
Click on this link below to access this activity: